Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jul 11;56(13):5505-13.
doi: 10.1021/jm4005219. Epub 2013 Jun 20.

Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance

Morgan Le Naour  1 , Eyup Akgün, Ajay Yekkirala, Mary M Lunzer, Mike D Powers, Alexander E Kalyuzhny, Philip S Portoghese
Affiliations

Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance

Morgan Le Naour et al. J Med Chem. .

Abstract

Given that μ opioid (MOP) and canabinoid (CB1) receptors are colocalized in various regions of the central nervous system and have been reported to associate as heteromer (MOP-CB1) in cultured cells, the possibility of functional, endogenous MOP-CB1 in nociception and other pharmacologic effects has been raised. As a first step in investigating this possibility, we have synthesized a series of bivalent ligands 1-5 that contain both μ agonist and CB1 antagonist pharmacophores for use as tools to study the functional interaction between MOP and CB1 receptors in vivo. Immunofluorescent studies on HEK293 cells coexpressing both receptors suggested 5 (20-atom spacer) to be the only member of the series that bridges the protomers of the heteromer. Antinociceptive testing in mice revealed 5 to be the most potent member of the series. As neither a mixture of monovalent ligands 9 + 10 nor bivalents 2-5 produced tolerance in mice, MOR-CB1 apparently is not an important target for reducing tolerance.

PubMed Disclaimer

Figures

Figure 2
Figure 2
Single cell high-magnification images of double-labeling immunofluorescence for co-expressed MOP and CB1 receptors on HEK-293 cells. The identical cells are shown labeled for MOP (red fluorescence) and CB1 (green fluorescence) receptors. Arrows depict profiles double-labeled for MOP and CB1.
Figure 2
Figure 2
Single cell high-magnification images of double-labeling immunofluorescence for co-expressed MOP and CB1 receptors on HEK-293 cells. The identical cells are shown labeled for MOP (red fluorescence) and CB1 (green fluorescence) receptors. Arrows depict profiles double-labeled for MOP and CB1.
Scheme 1
Scheme 1
Intermediates for synthesis of bivalent ligands 1-5 and monovalent ligands 9 and 10
Scheme 2
Scheme 2
Synthesis of target compounds (1-5, 10)
See this image and copyright information in PMC

References

    1. Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol., Biochem. Behav. 2005;81:360–368. - PubMed
    1. Mansour A, Khachaturian H, Lewis M, Akil H, Watson SJ. Anatomy of CNS opioid receptors. Trends NeuroSci. (Pers. Ed.) 1988;11:308–314. 2 plates. - PubMed
    1. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De CBR, Rice KC. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J. Neurosci. 1991;11:563–583. - PMC - PubMed
    1. Rodriguez JJ, Mackie K, Pickel VM. Ultrastructural localization of the CB1 cannabinoid receptor in μ-opioid receptor patches of the rat caudate putamen nucleus. J. Neurosci. 2001;21:823–833. - PMC - PubMed
    1. Parolaro D, Rubino T, Vigano D, Massi P, Guidali C, Realini N. Cellular mechanisms underlying the interaction between cannabinoid and opioid system. Curr. Drug Targets. 2010;11:393–405. - PubMed

Publication types

MeSH terms